PRMT5 inhibitor MRTX1719 for MTAP-deleted cancers, and selective SOS1 inhibitor MRTX0902. Last year, the Financial Times also reported that there was interest in a Mirati buyout, citing Merck as ...

Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer. Krazati has been cleared as a treatment for ...